Published Oct 2, 2026, 11:13 AM ET · Updated a month ago · 1 source
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
CNBC Markets
·
Original Report
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.